Miguel G. D.
- Country
- Spain
- Department
- Infectious Diseases
Research Overview
- Evaluation of the Impact of a Broadly Neutralizing Antibody and Attachment Inhibitor on Viral Reservoirs in HIV Patients on Integrase Inhibitor-Based Antiretroviral Therapy
- Efficacy and Safety of Islatravir and Ulonivirine Once Weekly versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Once Daily in Treatment-Naïve Adults with HIV-1
- Lenacapavir with Teropavimab and Zinlirvimab (twice‑yearly) versus Cabotegravir/Rilpivirine in virologically suppressed adults with HIV‑1
Data & Insights
Has run more than one trial at 63 of 114 partner sites.
Specializations
Oncology and immuno-oncology
The investigator is involved in clinical research across a wide range of solid and hematologic cancers, with a strong emphasis on lung cancer, melanoma, breast cancer, colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and urothelial carcinoma. The portfolio also includes studies in ovarian cancer, gastric cancer, pancreatic cancer, prostate cancer, and lymphoma.
- Immune checkpoint inhibitors
- Targeted therapy
- Adjuvant and perioperative cancer treatment
- Metastatic solid tumors
His oncologic interests extend to advanced and recurrent disease settings, including KRAS G12C-mutant tumors, MSI-H/dMMR colorectal cancer, and HER2-positive or hormone receptor-positive breast cancer.
Infectious diseases and antimicrobial therapy
As part of the Servicio de enfermedades Infecciosas in Valencia, the investigator contributes to trials in HIV infection, chronic hepatitis B, chronic hepatitis C, hepatitis D, and pulmonary tuberculosis. Research also includes treatment strategies for severe influenza, bacteremia, septic shock, and community-acquired pneumonia.
- HIV and antiretroviral therapy
- Viral hepatitis
- Tuberculosis
- Serious bacterial and respiratory infections
His infectious-disease portfolio also covers strongyloidiasis and prevention-focused studies in patients at risk of infectious complications.
Hepatology and liver disease
The investigator is active in clinical studies addressing non-alcoholic steatohepatitis (NASH), alcohol-related liver disease, hepatocellular carcinoma, primary biliary cholangitis, hepatic encephalopathy, and broader cirrhosis-related complications. His work also includes patients with chronic hepatitis and advanced liver dysfunction.
- NASH and metabolic liver disease
- Hepatocellular carcinoma
- Hepatic encephalopathy
- Chronic viral liver disease
These studies reflect an interest in therapeutic options for progressive liver disease and liver-related cancer care.
Cardiovascular medicine
His clinical research includes atherosclerotic cardiovascular disease, acute coronary syndrome, atrial fibrillation, heart failure, non-obstructive coronary artery disease, and aortic stenosis. The portfolio also extends to venous thromboembolism prevention and broader cardiovascular risk reduction.
- Atrial fibrillation and stroke prevention
- Heart failure
- Atherosclerotic cardiovascular disease
- Thrombotic and antiplatelet therapy
He also participates in studies focused on lipid lowering and prevention of major cardiovascular events.
Dermatology, autoimmune disease, and metabolic disorders
The investigator is involved in trials for atopic dermatitis, psoriasis, hidradenitis suppurativa, alopecia areata, vitiligo, and actinic keratosis. Additional research spans systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, type 1 diabetes mellitus, type 2 diabetes mellitus, obesity, and overweight.
- Inflammatory skin disease
- Autoimmune rheumatic disease
- Metabolic disease
- Ophthalmic complications of diabetes
His research landscape also includes diabetic retinopathy, macular edema, and other conditions linking systemic inflammation with organ-specific complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.